← All trials
NCT03869385
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Jul 31, 2021
- Completion date
- Oct 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 1662
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Friedrich Schiller UniversityLead sponsor
- GrifolsCollaborator
- University of GoettingenCollaborator
- Friedrich Schiller UniversityReponsible party - principal investigator
- German Research FoundationCollaborator
- Johannes Gutenburg UniversityCollaborator
- Sepsis FoundationCollaborator
- Friedrich Schiller UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.